Free shipping at $80
Nutrition
You're watching the scale, your protein and probably your muscle. Your bones are quietly involved too. Here's what researchers are finding about bone density during significant GLP-1 weight loss.
Your bones are extremely low-maintenance roommates.
They don't complain when your jeans get smaller.
They don't shed in the shower.
They don't send you a push notification when something changes.
Which makes them very easy to forget while you're losing weight.
But significant weight loss doesn't happen around your skeleton.
Your bones are part of the conversation too.
Researchers have known for years that losing a meaningful amount of weight can sometimes be accompanied by changes in bone turnover and bone mineral density.
Now that GLP-1 medications can produce much larger weight losses than many older obesity treatments, researchers are asking an important question:
what happens to bone while the weight is coming off?
The answer is more nuanced than:
“GLP-1s cause bone loss.”
Some clinical trials have found reductions in bone mineral density during GLP-1-associated weight loss.
Other research has not found an increased fracture risk.
And one particularly interesting randomized trial suggests that exercise may change the picture considerably.
So no, this is not a reason to panic about your skeleton.
It is a reason to remember that healthy weight loss involves more than the scale.
Bone looks permanent.
Biologically, it isn't.
Your skeleton is constantly being remodelled as old bone is broken down and new bone is formed.
Body weight also provides mechanical loading to the skeleton.
When body weight drops substantially, that mechanical environment changes.
Calorie restriction, changes in nutrient intake, hormonal changes and losses in lean mass may also influence what happens to bone during weight loss.
That means there is an important distinction to make:
if bone density changes while someone is losing substantial weight on a GLP-1, that does not automatically prove the medication itself damaged the bone.
The weight loss may be part of the explanation.
One of the most useful studies came from Denmark in 2024.
Researchers enrolled 64 adults who were already considered at increased fracture risk.
Most were postmenopausal women, and the average age was about 63.
Participants received either once-weekly semaglutide 1.0 mg or placebo for 52 weeks.
The researchers were primarily interested in a marker of bone formation called PINP.
Semaglutide did not significantly increase that bone-formation marker.
But researchers did see something else.
Compared with placebo, the semaglutide group had lower bone mineral density at the lumbar spine and total hip after 52 weeks.
They also lost more weight.
The estimated difference in body weight between groups was 6.8 kilograms.
Bone resorption, the process in which bone tissue is broken down, was also higher in the semaglutide group.
Importantly, the researchers themselves noted that the increase in bone resorption may have been explained by the accompanying weight loss.
That distinction matters.
This is where internet health information has a tendency to put on running shoes.
A study finds lower bone mineral density.
The headline becomes:
“GLP-1s destroy your bones.”
Those are not the same statement.
The semaglutide trial involved a small group of people who already had increased fracture risk.
It also produced meaningful weight loss.
And the study was not designed to determine whether semaglutide causes osteoporosis or fractures in the general population.
There is another important piece of evidence.
A 2025 systematic review and meta-analysis pooled randomized trials of GLP-1 receptor agonists in people with type 2 diabetes.
Across 25 included studies, GLP-1 treatment was not significantly associated with an increased risk of fracture.
Different population.
Different drugs and doses.
Different amounts of weight loss.
Different question.
Which is exactly why the evidence should not be flattened into one scary sentence.
The Quick Take
Bone density and fracture risk are not the same outcome.
A trial can detect a change in bone mineral density without proving that people taking GLP-1 medications experience more fractures.
Both questions matter.
They are not interchangeable.
Another randomized study gives us a practical clue.
Researchers studied 195 adults with obesity who first completed an eight-week low-calorie diet.
They were then randomized for one year to:
The combination group lost the most weight.
About 16.9 kilograms across the total study period.
And yet the combination of exercise and liraglutide preserved bone mineral density at the hip, spine and forearm compared with placebo.
Liraglutide without the structured exercise program was different.
That group showed greater reductions in hip and lumbar-spine bone mineral density than the exercise group, despite the exercise and liraglutide groups having similar amounts of weight loss.
The exercise group also increased lean mass.
The combination group preserved lean mass despite losing the most fat.
This doesn't prove that one particular workout prevents bone loss for everyone taking a GLP-1.
But it does give us a much more useful message than:
“Be scared of losing weight.”
Before you picture someone handing you a barbell and yelling:
“FOR YOUR FEMUR.”
The study's exercise program was broader than that.
Participants were encouraged to exercise four times per week.
Supervised sessions included vigorous indoor cycling and circuit training with aerobic and muscle-strengthening exercises.
Individual sessions could include cycling, running, brisk walking or circuit training.
So this wasn't a trial proving that one specific exercise is the magical answer for bone.
But bones respond to mechanical loading.
And maintaining muscle and physical function during weight loss matters for reasons that go well beyond how your body looks.
Bone Likes a Reason to Stay Strong
Movement is part of the bone conversation.
The best-supported strategy isn't “lose less weight.”
It's to think about what accompanies the weight loss.
GLP-1 medications can make eating substantially less feel surprisingly easy.
That is useful for weight loss.
It can also mean there is less food available to deliver everything your body needs.
Bone health depends on a bigger nutritional picture that includes adequate protein and nutrients involved in normal bone metabolism, including calcium and vitamin D.
That does not mean everyone taking a GLP-1 needs to start swallowing a collection of supplements.
More is not automatically better.
And a supplement cannot replace enough food, appropriate exercise or medical evaluation when someone is genuinely at risk for osteoporosis.
The useful question is simpler:
if your total food intake has changed dramatically, has the nutritional quality of what remains kept up?
Please Don't Build a Supplement Pyramid
More pills ≠ stronger bones.
Calcium, vitamin D, protein and overall nutrition matter.
But individual needs vary, and excessive supplementation is not a shortcut to better bone density.
If you have known osteoporosis, previous low-trauma fractures, significant nutritional restriction or other risk factors, your clinician can help determine whether testing or targeted supplementation makes sense.
Bone health deserves more individualized attention if you already have reasons to be at higher risk.
That may include people with:
That doesn't mean everyone in one of these groups should stop losing weight.
It means the conversation may need to include more than body weight.
Start here
If you're losing significant weight, think beyond the scale.
Bone responds to mechanical loading, and exercise can help preserve muscle and physical function during weight loss.
Protein supports muscle, and muscle is part of the larger musculoskeletal picture.
When total food intake falls, nutrient density becomes more important, not less.
If you already have osteoporosis, low bone density or fracture risk, talk with your clinician about what monitoring is appropriate for you.
Calcium, vitamin D and other nutrients matter, but supplementation should fit your actual needs.
Not automatically.
A GLP-1 prescription by itself is not a universal instruction to schedule a DXA scan.
Bone-density screening recommendations depend on factors such as age, sex, menopausal status, fracture history and individual clinical risk.
If you already have elevated fracture risk, have experienced a low-trauma fracture or are concerned about prolonged very low intake during substantial weight loss, that is a reasonable conversation to have with your healthcare provider.
Your skeleton does not need a panic meeting.
It may occasionally deserve a calendar invite.
The Bigger Idea
Healthy weight loss isn't just about what you lose.
It's also about what you preserve.
Muscle.
Strength.
Nutrition.
Function.
And yes, bone.
Significant weight loss can affect bone.
That was true before GLP-1 medications existed.
Now that these medications can produce substantial weight loss, researchers are paying closer attention to what happens to bone mineral density along the way.
A small randomized semaglutide trial in adults already at increased fracture risk found lower hip and lumbar-spine bone mineral density after 52 weeks compared with placebo.
But that does not establish that GLP-1 medications broadly cause osteoporosis or fractures.
In fact, pooled randomized evidence in people with type 2 diabetes has not shown a significant increase in fracture risk.
And another randomized trial offers an encouraging clue:
participants combining liraglutide with structured exercise lost the most weight while preserving bone mineral density at important skeletal sites compared with placebo.
The science is still developing.
Especially for the newer medications and the larger amounts of weight loss now possible.
For now, the useful lesson isn't:
“Be afraid of losing weight.”
It's:
don't let the scale become the only thing you're taking care of.
Eat with intention.
Keep using your body.
Protect your muscle.
Know your personal risk factors.
And remember the quiet roommates.
They've been holding you up this entire time.
The least we can do is include them in the group chat.
Hansen MS, Wölfel EM, Jeromdesella S, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine. 2024;72:102624. doi:10.1016/j.eclinm.2024.102624. PMID: 38737002. (Phase 2 RCT, 64 adults without diabetes at increased fracture risk, semaglutide 1.0 mg weekly, 52 weeks. Funded by the Region of Southern Denmark, Novo Nordisk Foundation and Gangsted Foundation; Novo Nordisk supplied drug and placebo.)
https://pmc.ncbi.nlm.nih.gov/articles/PMC11087719/
Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775. PMID: 38916894. (Prespecified secondary analysis, 195 adults with obesity without diabetes, liraglutide 3.0 mg daily, 52 weeks after an 8-week low-calorie diet. Funded in part by the Novo Nordisk Foundation; Novo Nordisk supplied liraglutide and placebo.)
https://pmc.ncbi.nlm.nih.gov/articles/PMC11200146/
Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetologica. 2025;62(5):589–606. doi:10.1007/s00592-025-02468-5. PMID: 39985672. (25 studies in type 2 diabetes; fracture RR 0.80, 95% CI 0.47–1.36.)
https://pubmed.ncbi.nlm.nih.gov/39985672/
Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181. doi:10.1016/j.obpill.2025.100181. PMID: 40673264.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/
U.S. Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening. Final Recommendation Statement. January 14, 2025.
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
NIH Office of Dietary Supplements. Calcium: Fact Sheet for Consumers.
https://ods.od.nih.gov/factsheets/Calcium-Consumer/
NIH Office of Dietary Supplements. Vitamin D: Fact Sheet for Consumers.
https://ods.od.nih.gov/factsheets/VitaminD-Consumer/
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Exercise for Your Bone Health.
https://www.niams.nih.gov/health-topics/exercise-your-bone-health
Bone Health & Osteoporosis Foundation. Are You At Risk?
https://www.bonehealthandosteoporosis.org/patients/what-is-osteoporosis/are-you-at-risk/
The Appendix provides general educational information and is not a substitute for individualized medical advice. Speak with your healthcare professional about questions specific to your health, medications or treatment.
TAKE next
Don't let a smaller appetite make nutrition an afterthought.
Significant weight loss changes more than the number on the scale. When you're eating less, paying attention to the nutrients your body still needs matters.*
COMPLETE
A daily multivitamin with vitamins, minerals and antioxidants, designed to support everyday nutrition while your intake is changing.*
